RIO DE JANEIRO, BRAZIL - According to Pluristem Therapeutics Inc., an Israeli regenerative medicine group, all patients were in the ICU with Covid-19, on ventilators, and suffering from acute respiratory syndrome. After the tests, which ran for a week, all improved and survived.
The treatment in question uses placenta, and is cell-based. Four out of the seven patients showed considerable improvement in their condition, considered severe, while three others were able to be taken off ventilators.
Four of the study subjects were in the so-called risk group, with comorbidities such as cardiovascular disease and renal failure. Nevertheless, they . . .